Add Company
Join Now

Anixa Biosciences Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Anixa Biosciences's estimated annual revenue is currently $2.3M per year.(i)
  • Anixa Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Anixa Biosciences has 15 Employees.(i)
  • Anixa Biosciences grew their employee count by 15% last year.

Anixa Biosciences's People

NameTitleEmail/Phone
1
President, COO & CFOReveal Email/Phone
2
Chief Development OfficerReveal Email/Phone
3
President, COO & CFOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Anixa Biosciences?

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company’s vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC). Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

keywords:N/A

N/A

Total Funding

15

Number of Employees

$2.3M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M15N/AN/A
#2
$15M15N/AN/A
#3
$0.5M150%N/A
#4
$1.3M15N/AN/A
#5
$4.8M15-65%N/A